Catalyst
Slingshot members are tracking this event:
Dermira (DERM) Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| DERM |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 31, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2b, Lebrikizumab, Atopic Dermatitis
